ERBB2 and breast cancer: The increased recruitment of TILs and their intratumoral expansion expected with the combination of IL-2 variant targeting fibroblast activation protein-alpha in combination with trastuzumab in phase I (NCT02627274) and 41BB/HER2-directed bispecific CD3-T cell engagers, NCT03330561 and NCT02829372, respectively, represent with CAR-T cells more examples of the growing interest of immunotherapy in BC.